Targeting VEGF in cancer therapy.
Donovan
Erin A
EA
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kummar
Shivaani
S
D000906:Antibodies / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000628:therapy; D015179:Colorectal Neoplasms / Q000628:therapy; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D008175:Lung Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
D000906:Antibodies; D016376:Oligonucleotides, Antisense; D042461:Vascular Endothelial Growth Factor A; D011505:Protein-Tyrosine Kinases